[Maxigen Biotech] May 2026 Revenue Reaches NT$73.6 Million (Down 4.4% YoY)
NQ Score
50/100
N1 Content Completeness
4
AI Summary (NQ-processed)
Maxigen Biotech Inc. (code: 1783), a biotechnology and medical care company, announced its May 2026 revenue of NT$73,604 thousand (approx. NT$74 million), representing a 4.4% decrease compared to the same period last year.
AI Analysis
Frequently Asked Questions
- Q: What is Maxigen Biotech's revenue for May 2026?
- A: The revenue for May 2026 is NT$73,604 thousand (approx. NT$74 million), representing a YoY decline of 4.4%.
- Q: What industry does Maxigen Biotech operate in?
- A: Maxigen Biotech operates within the 'Biotechnology and Medical Care' sector.
- Q: What is the strategic takeaway from the May 2026 revenue?
- A: While revenue decreased slightly by 4.4% YoY, it reflects minor monthly fluctuations rather than a major shift in fundamentals.